In recent years, ISKCON has continued to innovate in the field of independent research and development of targeted therapy technologies and products. With its high-level innovation and R&D capabilities, it has continuously won various honors, and has been awarded the honorary titles of "National High-tech Enterprise" and "AAA Credit Enterprise" Later, "Targeted Anti-tumor Immunotherapy Technology Development and Application" won the 2015 "Shenzhen Science and Technology Progress Award" again!

With the continuous changes in the living environment, the aging of the population and other factors have become increasingly serious, the incidence of malignant tumors has increased year by year, and the threat to humans has become increasingly prominent. Currently, it has become the number one killer threatening human health in developed countries and first-tier cities in my country.

Surgery, radiotherapy, chemotherapy and biological therapy are the four main methods of cancer treatment. However, after treatment, recurrent cancers due to residual cancer cells or due to drug resistance are often more malignant. Surgery, radiotherapy and chemotherapy and targeted drugs are helpless. Only targeted immunotherapy technology can break through this bottleneck. .

ISKCON’s ACTL targeted anti-tumor immune technology can accurately kill cancer cells remaining in the body after surgery, radiotherapy and chemotherapy, prevent recurrence and spread; it can also reverse the patient’s resistance to targeted drugs and endocrine drugs, and prolong The time for patients to benefit from such drugs; after diagnosis, the combination of ACTL technology and other treatments will have better treatment effects.

ACTL technology has reached the international advanced level, with strong targeting, high tumor-related antigen transfection rate, good therapeutic effect, wide application range (applicable to most solid tumors), high safety, and low side effects. With its distinctive technical characteristics, it has become a prominent representative of many domestic immunotherapy technologies. Thousands of patients have benefited from it and won praise from clinicians.

The Shenzhen Science and Technology Award is known as the "Oscar" of Shenzhen Science and Technology. The Shenzhen Science and Technology Progress Award is awarded to organizations or enterprises that have made outstanding contributions in the application and promotion of advanced scientific and technological achievements, and the completion of major scientific and technological projects, plans, and projects.

Ishikoning’s research and development and innovation in the field of targeted immunotherapy technology conform to the international development trend of tumor therapy and the national precision medicine development strategy. It provides tumor patients with high-quality products and services, and provides patients with new The treatment method has created huge social and economic benefits for the country and society, and further promoted the development of domestic anti-tumor precision treatment.

While pursuing economic benefits, the company always takes social development as its own responsibility, takes human health as its goal, and considers the mission of creating more reliable, more economical and more perfect treatment technology for patients. It continues to make breakthroughs in independent research and development and innovation. We will continue to spread our wings in the field of anti-tumor and anti-viral targeted therapy with high-quality and high-quality products and services!